Fast Five Quiz: Bladder Cancer Management

Kyle A. Richards, MD


January 13, 2020

Figure 1. Bladder Cancer

Assuming curative intent, both the EAU and NCCN recommend RC as the treatment of choice for MIBC.

The EAU further recommends pelvic lymph node dissection following RC to improve survival after RC, although no data are currently available to support this recommendation.

Along with RC as the primary treatment for all muscle-invasive disease, the NCCN strongly advises cisplatin-based neoadjuvant chemotherapy (category 1 recommendation)—particularly for patients with hydronephrosis, vascular/lymphatic invasion, extravesical disease, or aberrant histologic variants.

Learn more about EUA and the NCCN guideline recommendations for the treatment of bladder cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.